 | • レポートコード：MRC23Q37903 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のミルベマイシンオキシム市場について調査・分析し、世界のミルベマイシンオキシム市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（125mg/錠、625mg/錠）、用途別セグメント分析（小売薬局、病院薬局、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Boehringer-Ingelheim、Virbac、Ceva、Krka、Elanco、Novartis、Purinaなどが含まれています。 世界のミルベマイシンオキシム市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ミルベマイシンオキシム市場規模を推定する際に考慮しました。本レポートは、ミルベマイシンオキシムの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ミルベマイシンオキシムに関するビジネス上の意思決定に役立てることを目的としています。 ・ミルベマイシンオキシム市場の概要 - 製品の定義 - ミルベマイシンオキシムのタイプ別セグメント - 世界のミルベマイシンオキシム市場規模：タイプ別分析（125mg/錠、625mg/錠） - ミルベマイシンオキシムの用途別セグメント - 世界のミルベマイシンオキシム市場規模：用途別分析（小売薬局、病院薬局、その他） - 世界のミルベマイシンオキシム市場規模予測（2018年-2029年） - ミルベマイシンオキシムの平均価格推移（2018年-2029年） - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - ミルベマイシンオキシム市場の競争状況およびトレンド ・ミルベマイシンオキシムの地域別市場規模 - 北米のミルベマイシンオキシム市場規模（2018年-2029年） - アメリカのミルベマイシンオキシム市場規模（2018年-2029年） - ヨーロッパのミルベマイシンオキシム市場規模（2018年-2029年） - アジア太平洋のミルベマイシンオキシム市場規模（2018年-2029年） - 中国のミルベマイシンオキシム市場規模（2018年-2029年） - 日本のミルベマイシンオキシム市場規模（2018年-2029年） - 韓国のミルベマイシンオキシム市場規模（2018年-2029年） - インドのミルベマイシンオキシム市場規模（2018年-2029年） - オーストラリアのミルベマイシンオキシム市場規模（2018年-2029年） - 中南米のミルベマイシンオキシム市場規模（2018年-2029年） - 中東・アフリカのミルベマイシンオキシム市場規模（2018年-2029年） ・タイプ別セグメント：125mg/錠、625mg/錠 - 世界のミルベマイシンオキシムのタイプ別販売量（2018年-2023年） - 世界のミルベマイシンオキシムのタイプ別売上（2018年-2023年） - 世界のミルベマイシンオキシムのタイプ別価格 ・用途別セグメント：小売薬局、病院薬局、その他 - 世界のミルベマイシンオキシムの用途別販売量（2018年-2023年） - 世界のミルベマイシンオキシムの用途別売上（2018年-2023年） - 世界のミルベマイシンオキシムの用途別価格 ・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向 Boehringer-Ingelheim、Virbac、Ceva、Krka、Elanco、Novartis、Purina ・産業チェーンと販売チャネルの分析 - ミルベマイシンオキシム産業チェーン分析 - ミルベマイシンオキシムの主要原材料 - ミルベマイシンオキシムの販売チャネル - ミルベマイシンオキシムのディストリビューター - ミルベマイシンオキシムの主要顧客 ・ミルベマイシンオキシム市場ダイナミクス - ミルベマイシンオキシムの業界動向 - ミルベマイシンオキシム市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Used in dogs to treat fleas and clams, and to prevent heartworm disease/or treat the following types of intestinal nematode infections: roundworms (canis roundworms and Leonina toxoplasma), hookworms (canine hookworms) and whipworms (vulvar whipworms) ).
Highlights
The global Milbemicina Oxima market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Milbemicina Oxima is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Milbemicina Oxima is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Milbemicina Oxima include Boehringer-Ingelheim, Virbac, Ceva, Krka, Elanco, Novartis and Purina, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Milbemicina Oxima, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Milbemicina Oxima.
The Milbemicina Oxima market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Milbemicina Oxima market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Milbemicina Oxima manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Boehringer-Ingelheim
Virbac
Ceva
Krka
Elanco
Novartis
Purina
Segment by Type
125mg/tablet
625mg/tablet
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Milbemicina Oxima manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Milbemicina Oxima in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Milbemicina Oxima Market Overview
1.1 Product Overview and Scope of Milbemicina Oxima
1.2 Milbemicina Oxima Segment by Type
1.2.1 Global Milbemicina Oxima Market Value Comparison by Type (2023-2029)
1.2.2 125mg/tablet
1.2.3 625mg/tablet
1.3 Milbemicina Oxima Segment by Application
1.3.1 Global Milbemicina Oxima Market Value by Application: (2023-2029)
1.3.2 Retail Pharmacy
1.3.3 Hospital Pharmacy
1.3.4 Others
1.4 Global Milbemicina Oxima Market Size Estimates and Forecasts
1.4.1 Global Milbemicina Oxima Revenue 2018-2029
1.4.2 Global Milbemicina Oxima Sales 2018-2029
1.4.3 Global Milbemicina Oxima Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Milbemicina Oxima Market Competition by Manufacturers
2.1 Global Milbemicina Oxima Sales Market Share by Manufacturers (2018-2023)
2.2 Global Milbemicina Oxima Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Milbemicina Oxima Average Price by Manufacturers (2018-2023)
2.4 Global Milbemicina Oxima Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Milbemicina Oxima, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Milbemicina Oxima, Product Type & Application
2.7 Milbemicina Oxima Market Competitive Situation and Trends
2.7.1 Milbemicina Oxima Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Milbemicina Oxima Players Market Share by Revenue
2.7.3 Global Milbemicina Oxima Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Milbemicina Oxima Retrospective Market Scenario by Region
3.1 Global Milbemicina Oxima Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Milbemicina Oxima Global Milbemicina Oxima Sales by Region: 2018-2029
3.2.1 Global Milbemicina Oxima Sales by Region: 2018-2023
3.2.2 Global Milbemicina Oxima Sales by Region: 2024-2029
3.3 Global Milbemicina Oxima Global Milbemicina Oxima Revenue by Region: 2018-2029
3.3.1 Global Milbemicina Oxima Revenue by Region: 2018-2023
3.3.2 Global Milbemicina Oxima Revenue by Region: 2024-2029
3.4 North America Milbemicina Oxima Market Facts & Figures by Country
3.4.1 North America Milbemicina Oxima Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Milbemicina Oxima Sales by Country (2018-2029)
3.4.3 North America Milbemicina Oxima Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Milbemicina Oxima Market Facts & Figures by Country
3.5.1 Europe Milbemicina Oxima Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Milbemicina Oxima Sales by Country (2018-2029)
3.5.3 Europe Milbemicina Oxima Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Milbemicina Oxima Market Facts & Figures by Country
3.6.1 Asia Pacific Milbemicina Oxima Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Milbemicina Oxima Sales by Country (2018-2029)
3.6.3 Asia Pacific Milbemicina Oxima Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Milbemicina Oxima Market Facts & Figures by Country
3.7.1 Latin America Milbemicina Oxima Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Milbemicina Oxima Sales by Country (2018-2029)
3.7.3 Latin America Milbemicina Oxima Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Milbemicina Oxima Market Facts & Figures by Country
3.8.1 Middle East and Africa Milbemicina Oxima Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Milbemicina Oxima Sales by Country (2018-2029)
3.8.3 Middle East and Africa Milbemicina Oxima Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Milbemicina Oxima Sales by Type (2018-2029)
4.1.1 Global Milbemicina Oxima Sales by Type (2018-2023)
4.1.2 Global Milbemicina Oxima Sales by Type (2024-2029)
4.1.3 Global Milbemicina Oxima Sales Market Share by Type (2018-2029)
4.2 Global Milbemicina Oxima Revenue by Type (2018-2029)
4.2.1 Global Milbemicina Oxima Revenue by Type (2018-2023)
4.2.2 Global Milbemicina Oxima Revenue by Type (2024-2029)
4.2.3 Global Milbemicina Oxima Revenue Market Share by Type (2018-2029)
4.3 Global Milbemicina Oxima Price by Type (2018-2029)
5 Segment by Application
5.1 Global Milbemicina Oxima Sales by Application (2018-2029)
5.1.1 Global Milbemicina Oxima Sales by Application (2018-2023)
5.1.2 Global Milbemicina Oxima Sales by Application (2024-2029)
5.1.3 Global Milbemicina Oxima Sales Market Share by Application (2018-2029)
5.2 Global Milbemicina Oxima Revenue by Application (2018-2029)
5.2.1 Global Milbemicina Oxima Revenue by Application (2018-2023)
5.2.2 Global Milbemicina Oxima Revenue by Application (2024-2029)
5.2.3 Global Milbemicina Oxima Revenue Market Share by Application (2018-2029)
5.3 Global Milbemicina Oxima Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Boehringer-Ingelheim
6.1.1 Boehringer-Ingelheim Corporation Information
6.1.2 Boehringer-Ingelheim Description and Business Overview
6.1.3 Boehringer-Ingelheim Milbemicina Oxima Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Boehringer-Ingelheim Milbemicina Oxima Product Portfolio
6.1.5 Boehringer-Ingelheim Recent Developments/Updates
6.2 Virbac
6.2.1 Virbac Corporation Information
6.2.2 Virbac Description and Business Overview
6.2.3 Virbac Milbemicina Oxima Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Virbac Milbemicina Oxima Product Portfolio
6.2.5 Virbac Recent Developments/Updates
6.3 Ceva
6.3.1 Ceva Corporation Information
6.3.2 Ceva Description and Business Overview
6.3.3 Ceva Milbemicina Oxima Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Ceva Milbemicina Oxima Product Portfolio
6.3.5 Ceva Recent Developments/Updates
6.4 Krka
6.4.1 Krka Corporation Information
6.4.2 Krka Description and Business Overview
6.4.3 Krka Milbemicina Oxima Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Krka Milbemicina Oxima Product Portfolio
6.4.5 Krka Recent Developments/Updates
6.5 Elanco
6.5.1 Elanco Corporation Information
6.5.2 Elanco Description and Business Overview
6.5.3 Elanco Milbemicina Oxima Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Elanco Milbemicina Oxima Product Portfolio
6.5.5 Elanco Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Milbemicina Oxima Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Novartis Milbemicina Oxima Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Purina
6.6.1 Purina Corporation Information
6.6.2 Purina Description and Business Overview
6.6.3 Purina Milbemicina Oxima Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Purina Milbemicina Oxima Product Portfolio
6.7.5 Purina Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Milbemicina Oxima Industry Chain Analysis
7.2 Milbemicina Oxima Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Milbemicina Oxima Production Mode & Process
7.4 Milbemicina Oxima Sales and Marketing
7.4.1 Milbemicina Oxima Sales Channels
7.4.2 Milbemicina Oxima Distributors
7.5 Milbemicina Oxima Customers
8 Milbemicina Oxima Market Dynamics
8.1 Milbemicina Oxima Industry Trends
8.2 Milbemicina Oxima Market Drivers
8.3 Milbemicina Oxima Market Challenges
8.4 Milbemicina Oxima Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer